NCT02686372View on ClinicalTrials.gov

A Study of TCR-Redirected T Cell Infusion to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 16, 2018

Primary Completion Date

September 28, 2021

Study Completion Date

September 28, 2021

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

TCR-T

Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR

BIOLOGICAL

No intervention and TCR-T (at crossover)

Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR

Trial Locations (1)

510080

The First Affiliated Hospital, Sun-Yat Sen University, Guangzhou

All Listed Sponsors
collaborator

First Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

lead

Lion TCR Pte. Ltd.

INDUSTRY

NCT02686372 - A Study of TCR-Redirected T Cell Infusion to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation | Biotech Hunter | Biotech Hunter